A Model to Estimate Frozen Tissue Collection Targets in Biobanks to Support Cancer Research

Biopreservation and Biobanking

Volumn 13, Issue 5, 2015, Pages 356-362

  Meredith, Anna J ^a   Slotty, Alex ^a   Matzke, Lise ^a   Babinszky, Sindy ^a   Watson, Peter H ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD SAMPLING; BREAST TUMOR; CANCER RESEARCH; CANCER TISSUE; COLORECTAL TUMOR; HUMAN; LUNG TUMOR; OVARY TUMOR; PRIORITY JOURNAL; PROSTATE TUMOR; TRANSLATIONAL RESEARCH; TUMOR CELL; TUMOR LOCALIZATION; TUMOR RECURRENCE; CRYOPRESERVATION; HEALTH CARE FACILITY; LABORATORY DIAGNOSIS; MEDICAL RESEARCH; NEOPLASM; PATHOLOGY; STATISTICS AND NUMERICAL DATA; THEORETICAL MODEL;

BIOLOGICAL SPECIMEN BANKS; BIOMEDICAL RESEARCH; CRYOPRESERVATION; HUMANS; MODELS, THEORETICAL; NEOPLASMS; SPECIMEN HANDLING;

EID: 84945268284     PISSN: 19475535     EISSN: 19475543     Source Type: Journal    
DOI: 10.1089/bio.2014.0081     Document Type: Article

References (21)

1. Castillo-Pelayo T, Babinszky S, LeBlanc J, Watson PH. The importance of biobanking to cancer research. Biopreserv Biobank 2015;13:172-177.
2. Biobanking and Biomolecular Resources Research Infrastructure [Internet]. 23:06:06 [cited 2014 Aug 22]. Available from: http://bbmri-eric.eu/.
3. Hewitt R, Watson P. Defining biobank. Biopreserv Biobank 2013;11:309-315.
4. Watson PH, Nussbeck SY, Carter C, et al. A framework for biobank sustainability. Biopreserv Biobanki 2014;12:60-68.
5. Watson PH, Barnes RO. A proposed schema for classifying human research biobanks. Biopreserv Biobank 2011;9:327-333.
6. Watson PH. Biobank classification: Communicating biorepository diversity. Biopreserv Biobank 2014;12:163-164.
7. Hughes SE, Barnes RO, Watson PH. Biospecimen use in cancer research over two decades. Biopreserv Biobank 2010;8:89-97.
8. Cole A, Cheah S, Dee S, Hughes S, Watson PH. Biospecimen use correlates with emerging techniques in cancer research: Impact on planning future biobanks. Biopreserv Biobank 2012;10:518-525.
9. Braun L, Lesperance M, Mes-Massons A-M, Tsao MS,Watson PH. Individual investigator profiles of biospecimen use in cancer research. Biopreserv Biobank 2014;12:192-198.
10. Barnes RO, Schacter B, Kodeeswaran S, Watson PH. Funding sources for Canadian biorepositories: The role of user fees and strategies to help fill the gap. Biopreserv Biobank 2014;12:300-305.
11. Canadian Tumour Repository Network URL [Internet]. 23:05:50 [cited 2013 Aug 2]. Available from: http:// www.ctrnet.ca/.
12. Watson PSB, SawyerM, Mes-MessonM, Gibson S, Shepherd L, Kodeeswaran S. Canadian Tumor Repository Network. Biobank profiles. Biopreserv Biobank 2010;8:181-184.
13. Canadian Cancer Research Alliance; Cancer Research Investment in Canada, 2010 [Internet]. 23:06:06 [cited 2014 Aug 22]. Available from: http://www.ccra-acrc.ca/index.php/ publications-en/investment-reports-annual/item/cancer-researchinvestment-in-canada-2010
14. Matzke EAM, O'Donoghue S, Barnes RO, et al. Certification for Biobanks: The program developed by the Canadian Tumour Repository Network (CTRNet). Biopreserv Biobank 2012;10:426-432.
15. Vaught J, Abayomi A, Peakman T, Watson P, Matzke L, Moore H. Critical issues in international biobanking. Clin Chem 2014;60:1368-1374.
16. Vaught J, Kelly A, Hewitt R. A review of international biobanks and networks: Success factors and key benchmarks. Biopreserv Biobank 2009;7:143-150.
17. Watson PH, Ravid R, Eng CB, Litton J-E, Vaught J, Matusan A. What are the main roadblocks to transnational biobank collaboration, and how can we overcome them? Biopreserv Biobank 2011;9:213-216.
18. Simeon-Dubach D, Watson P. Biobanking 3.0: Evidence based and customer focused biobanking. Clin Biochem 2014;47:300-308.
19. West NR, Milne K, Truong PT, Macpherson N, Nelson BH, Watson PH. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res BCR 2011;13:R126.
20. West NR, Murray JI, Watson PH. Oncostatin-M promotes phenotypic changes associated with mesenchymal and stem cell-like differentiation in breast cancer. Oncogene [Internet]. 2013 Apr 15; Available from: http://www.ncbi.nlm .nih.gov/pubmed/23584474.
21. West NR, Murphy LC, Watson PH. Oncostatin M suppresses oestrogen receptor-alpha expression and is associated with poor outcome in human breast cancer. Endocr Relat Cancer 2012;19:181-195.